Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,846 matching trials from the live ClinicalTrials.gov search.
Filters: "gene therapy" Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

NCT05217641
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 4, 2026, 1:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

Avo In R/R And Previously Untreated MCL

NCT04855695
View directory record Official record
Conditions
Mantle Cell Lymphoma, Refractory Lymphoma
Interventions
Acalabrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Austin I Kim
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT06161519
View directory record Official record
Conditions
Glioma, Medulloblastoma, Ependymoma, Glioblastoma
Interventions
PLX038
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Suspended Early Phase 1 Interventional

PBA Use for Treatment of ATF6-/- Patients

NCT04041232
View directory record Official record
Conditions
ACHROMATOPSIA 7, Achromatopsia
Interventions
PBA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Not listed No phase listed Observational

Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection

NCT02017587
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Vaccine and Gene Therapy Institute, Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 4, 2026, 1:18 AM EDT
Completed No phase listed Observational

Rapid Diagnostic Supporting Antimicrobial Stewardship in Patients With Pneumonia

NCT05937126
View directory record Official record
Conditions
Lower Respiratory Tract Infections
Interventions
FilmArray Pneumonia Panel, Culture and antimicrobial susceptibility testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

NCT01209325
View directory record Official record
Conditions
Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
13 Years to 26 Years · Male only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 4, 2026, 1:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites

NCT07607158
View directory record Official record
Conditions
Microbiome Analysis, Metabolomics
Interventions
Freeze-dried blueberry powder beverage
Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Not listed Phase 2 Interventional Results available

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

NCT04096417
View directory record Official record
Conditions
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR2 Gene Translocation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, FGFR3 Gene Translocation, Metastatic Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Pemigatinib, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

NCT01326104
View directory record Official record
Conditions
Medulloblastoma, Neuroectodermal Tumor
Interventions
TTRNA-xALT, TTRNA-DCs
Biological
Lead sponsor
University of Florida
Other
Eligibility
Up to 30 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Canola Oil Multi-Centre Intervention Trial II

NCT02029833
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Metabolic Syndrome
Interventions
Regular Canola Oil, High Oleic Canola Oil, Western Type Diet - Common Dietary Oils
Other
Lead sponsor
University of Manitoba
Other
Eligibility
20 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 4, 2026, 1:18 AM EDT
Not yet recruiting Early Phase 1 Interventional

A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.

NCT07813533
View directory record Official record
Conditions
Epidermal Nevi
Interventions
sirolimus topical gel 0.2%
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Phase 4 Interventional

D-Cycloserine for Serine Palmitoyltransferase Inhibition

NCT07542548
View directory record Official record
Conditions
Hereditary Spastic Paraplegia
Interventions
D-cycloserine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 6 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Completed No phase listed Observational

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma

NCT00339963
View directory record Official record
Conditions
Leukemia, Multiple Myeloma, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year and older
Enrollment
1,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Phase 3 Interventional Results available

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

NCT00288704
View directory record Official record
Conditions
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Interventions
rilonacept 160 mg, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Phase 2 Interventional

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

NCT00006033
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene therapy, interleukin-2 gene, methotrexate
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 4, 2026, 1:18 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

NCT05572463
View directory record Official record
Conditions
Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
Interventions
Sintilimab + IBI110
Combination Product
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
San Francisco, California • Detroit, Michigan • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

NCT00002748
View directory record Official record
Conditions
Neuroblastoma
Interventions
gene-modified tumor cell vaccine therapy, interleukin-2 gene
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 4, 2026, 1:18 AM EDT
Active, not recruiting Phase 1 Interventional

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

NCT03635632
View directory record Official record
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor
Interventions
C7R-GD2.CART cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 74 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Recruiting No phase listed Observational

Individualized AML Treatment

NCT07613385
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions
Observational
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Completed Phase 1 Interventional

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072
View directory record Official record
Conditions
Secondary Pulmonary Arterial Hypertension
Interventions
Heart Catheterization
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 1:18 AM EDT
Completed No phase listed Observational

Diagnostic and Screening Study of Genetic Disorders

NCT00006057
View directory record Official record
Conditions
Tay-Sachs Disease, Porphyria, Erythropoietic, Leukodystrophy, Globoid Cell, Metabolism, Inborn Errors
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 1:18 AM EDT
Completed No phase listed Observational

Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer

NCT00071357
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 1:18 AM EDT